Immuron (NASDAQ: IMRN) reports AUD$4.2m H1 Travelan sales growth
Rhea-AI Filing Summary
Immuron Limited reports unaudited first-half global sales of Travelan® of AUD$4.2 million, up 5% on the prior comparative period. Second-quarter sales were AUD$2.2 million, 11% higher than the prior quarter, reflecting continued momentum.
In Australia, H1 sales reached AUD$3.3 million, up 13% on the prior period, with Q2 at AUD$1.7 million, also up 11%. Growth was driven by digital and social media marketing, stronger in‑store promotion, new store rollouts, and increased South East Asian travel, partially offset by a one‑off stock reduction by a major pharmacy group. Immuron also launched its new product ProIBS® into the Australian market.
In the U.S., H1 sales were AUD$0.9 million, up 17% on the prior period, aided by Amazon store improvements and expanded social media marketing. In Canada, H1 sales were AUD$56 thousand, down 85% on the prior period due to prior pipeline fill, but Q2 sales of AUD$42 thousand rose 191% on the prior quarter, with further distribution planned, including a Travelan® launch into Jean Coutu pharmacies in 3QFY26.
Positive
- None.
Negative
- None.
Insights
Immuron shows modest Travelan® sales growth with expanding distribution, but changes appear incremental.
Immuron reports unaudited H1 Travelan® sales of
U.S. H1 sales of
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of January 2026
Commission File Number: 001-38104
IMMURON LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
IMMURON LIMITED
EXPLANATORY NOTE
Immuron Limited (the “Company”) published an announcement (the “Public Notices”) to the Australian Securities Exchange on January 19, 2026, titled:
99.1 Immuron Continued Sales Growth
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
1
EXHIBITS
| Exhibit Number |
Description | |
| 99.1 | Immuron Continued Sales Growth |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMMURON LIMITED | ||
| Date: January 20, 2026 | By: | /s/ Phillip Hains |
| Phillip Hains | ||
| Company Secretary | ||
3
Exhibit 99.1
ASX Announcement
Immuron Continued Sales Growth
Sales Highlights (unaudited):
| Global | ● | H1 sales AUD$4.2 million up 5% on prior comparative period (pcp) |
| ● | Q2 sales AUD$2.2 million up 11% on prior quarter | |
| Australia | ● | H1 sales AUD$3.3 million up 13% on prior comparative period (pcp) |
| ● | Q2 sales AUD$1.7 million up 11% on prior quarter | |
| ● | Australian launch of ProIBS® | |
| Canada | ● | H1 sales AUD$56 thousand down 85% on prior comparative period (pcp) |
| ● | Q2 sales AUD$42 thousand up 191% on prior quarter | |
| USA | ● | H1 sales AUD$0.9 million up 17% on prior comparative period (pcp) |
| ● | Q2 sales AUD$0.4 million up 8% on prior quarter |
Melbourne, Australia, January 19, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.
Continued Travelan® H1 sales growth (+11% on pcp) in Australia can be contributed to: (1) increased awareness and consideration driven by extensive digital and social media marketing. (2) same store growth as a result of increased promotion and past promotions driving new customers and return customers respectively; (3) growth from new stores within banner groups in which we secured core ranging in FY25; (4) increased South East Asian travel. These growth factors were offset by a one-off reduction of stock holding by the merged Sigma Healthcare/Chemist Warehouse group.
Although it is difficult launching close to year end, we managed to launch ProIBS® (https://investors.immuron.com.au/announcements/7225649) prior to Christmas ahead of schedule to gain some early opportunities. ProIBS® is stocked by two of the three largest pharmacy wholesalers with listings in five banner groups. 2026 category reviews provides us with the opportunity for additional listings. We believe that once Australian consumers try ProIBS®, they will love it!
H1 sales in the U.S. increased (+17% on pcp) on the back on number of marketing initiatives including: (1) improved Travelan® store on Amazon.com; (2) local U.S. Travelan® Facebook and Instagram pages; (3) increased paid social, influencer and organic social media marketing.
During FY25 we had a Q1 pipeline fill into over a thousand Canada retail doors on the back of securing listings within key pharmacy and grocery retail groups. As expected, sales picked up on the back of consumer promotions in Q2 FY26 (+191% on prior quarter). We anticipate a continued increase in pull through from stores as we continue to build Travelan® brand awareness within Canada though our in-store educational programs, in-store promotions, and social media marketing.
Travelan® will be launched into Jean Coutu pharmacies in 3QFY26. Jean Coutu is the number one or two pharmacy group in Quebec, the second largest province in Canada by population.
This release has been authorised by the directors of Immuron Limited.
|
Steven Lydeamore Chief Executive Officer steve@immuron.com |
2
About Travelan®
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a purified tablet preparation of hyper-immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with traveler’s diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveler’s Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveler’s Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
Immuron Platform Technology
Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.
For more information visit: https://www.immuron.com.au/ and https://www.travelan.com
Sign up to Immuron’s Investor Hub: Here
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
3
FAQ
What were Immuron (IMRN) global Travelan H1 2026 sales and growth?
How did Immuron (IMRN) perform in the Australian market in H1 2026?
What were Immuron (IMRN) Travelan H1 2026 sales in the U.S. and how much did they grow?
Why did Immuron (IMRN) Canadian Travelan sales drop in H1 2026 but rise in Q2?
What new product and distribution initiatives did Immuron (IMRN) announce?
Is the Immuron (IMRN) sales data in this update audited?
